Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
NEW YORK - Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reported fourth quarter revenue of $1.33 million, sending shares down 3.9% in after-hours trading. The clinical-stage biotechnology company, focused on developing antibody complement therapeutics for autoimmune diseases, posted a quarterly loss of $0.81 per share.
The company’s fourth quarter revenue performance overshadowed its progress in clinical trials for its lead candidate, DNTH103. Dianthus remains on track to report top-line data from its Phase 2 trial in generalized Myasthenia Gravis (gMG) in the second half of 2025. Additionally, the company’s Phase 3 CAPTIVATE trial for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is progressing, with an interim responder analysis expected in the second half of 2026.
Marino Garcia, Chief Executive Officer of Dianthus Therapeutics, stated, "We remain on track to report top-line data in 2H’25 from our Phase 2 clinical trial of DNTH103 in gMG, an indication where a best-in-class, potent active C1s and classical pathway inhibitor with the potential for effective and consistent symptom control along with improved safety and convenience could meaningfully advance the standard of care."
For the full year 2024, Dianthus reported research and development expenses of $83.1 million, up from $32.8 million in 2023, reflecting increased clinical and manufacturing costs for DNTH103. General and administrative expenses rose to $25.0 million from $18.2 million the previous year.
The company ended 2024 with a strong cash position of $357.0 million, which it projects will provide runway into the second half of 2027. Despite the revenue miss, Dianthus continues to advance its clinical pipeline, with top-line results from its Phase 2 trial in Multifocal Motor Neuropathy also expected in the second half of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.